Truqap, one of the potential jewels in AstraZeneca’s oncology portfolio, failed a late-stage trial in prostate cancer. CVS Health delivered Q1 results that beat Wall Street expectations, but said its ...

AstraZeneca said the safety and tolerability profile for Truqap was consistent with other trials. This is another blow for one of AstraZeneca’s flagship oncology products, which failed to meet the ...

AstraZeneca said the safety and tolerability profile for Truqap was consistent with other trials. This is another blow for one of AstraZeneca’s flagship oncology products, which failed to meet the ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the blockbuster potential of the first-in-class cancer treatment. Alongside its ...

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts the Truqap trial in prostate cancer.

AstraZeneca said that it was discontinuing the CAPITello-280 phase 3 trial for Truqap, its prostrate cancer treatment, as it wasn't likely to meet the dual primary endpoints. The Anglo-Swedish ...

Separately, AstraZeneca discontinued a Phase III trial of Truqap in metastatic prostate cancer after interim analysis showed the drug was unlikely to meet its endpoints. AstraZeneca shares fall as ...

AstraZeneca’s (AZ) AKT inhibitor Truqap (capivasertib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for advanced breast ...

AstraZeneca’s Truqap (capivasertib) has been approved for use by the National Health Service (NHS) in England and Wales, providing a new targeted therapy option that significantly increases ...

We've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer that ...